PriceTargets.com logo

Aspira Women's Health - AWH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $30.00
  • Forecasted Upside: 757.14%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.50 As of 05/26/2023 05:00 PM ET
▼ -0.24 (-6.42%)

This chart shows the closing price for AWH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aspira Women's Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AWH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AWH

Analyst Price Target is $30.00
▲ +757.14% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aspira Women's Health in the last 3 months. The average price target is $30.00, with a high forecast of $30.00 and a low forecast of $30.00. The average price target represents a 757.14% upside from the last price of $3.50.

This chart shows the closing price for AWH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Aspira Women's Health. This rating has held steady since March 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/20/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral$45.00 ➝ $30.00Low
9/2/2022William BlairReiterated RatingMarket PerformLow
1/11/2022Cantor FitzgeraldReiterated RatingOverweightHigh
7/9/2021Cantor FitzgeraldReiterated RatingOverweightHigh
3/29/2021Truist FinancialInitiated CoverageBuy$180.00N/A
1/28/2021Cantor FitzgeraldInitiated CoverageOverweight$150.00High
10/31/2020MacquarieReiterated RatingHoldLow
10/30/2020MacquarieReiterated RatingHoldLow
10/30/2020William BlairReiterated RatingOutperformHigh
10/29/2020William BlairInitiated CoverageOutperformHigh
10/14/2020Brookline Capital ManagementReiterated RatingBuyHigh
(Data available from 5/30/2018 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
11/30/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 3 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2023
  • 5 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
5/29/2023

Current Sentiment

  • 5 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aspira Women's Health logo
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
Read More

Today's Range

Now: $3.50
Low: $3.40
High: $4.02

50 Day Range

MA: $5.75
Low: $3.50
High: $53.85

52 Week Range

Now: $3.50
Low: $3.26
High: $16.50

Volume

24,100 shs

Average Volume

20,852 shs

Market Capitalization

$29.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Aspira Women's Health?

The following Wall Street research analysts have issued research reports on Aspira Women's Health in the last year: Cantor Fitzgerald, StockNews.com, and William Blair.
View the latest analyst ratings for AWH.

What is the current price target for Aspira Women's Health?

1 Wall Street analysts have set twelve-month price targets for Aspira Women's Health in the last year. Their average twelve-month price target is $30.00, suggesting a possible upside of 757.1%. Cantor Fitzgerald has the highest price target set, predicting AWH will reach $30.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $30.00 for Aspira Women's Health in the next year.
View the latest price targets for AWH.

What is the current consensus analyst rating for Aspira Women's Health?

Aspira Women's Health currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AWH, but not buy more shares or sell existing shares.
View the latest ratings for AWH.

What other companies compete with Aspira Women's Health?

Other companies that are similar to Aspira Women's Health include Biomerica, OncoCyte, Trinity Biotech, Nymox Pharmaceutical and Lucira Health. Learn More about companies similar to Aspira Women‘s Health.

How do I contact Aspira Women's Health's investor relations team?

Aspira Women's Health's physical mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company's listed phone number is 512-519-0400 and its investor relations email address is [email protected]. The official website for Aspira Women's Health is www.aspirawh.com. Learn More about contacing Aspira Women‘s Health investor relations.